Experiments showed that TT-LDCP nanoparticles that co-delivered PD-L1 siRNA and IL-2 Pdna could reverse the immunosuppressive TME of HCC by increasing tumoral infiltration CD8+ T cells and promote the maturation of tumor-infiltrating DCs. The gene discussed is CD8A; the disease is hepatocellular carcinoma.